MRDAC - MR development and application center
DCE-MRI

DCE-MRI (Dynamic contrast-enhanced magnetic resonance imaging) is the key method to evaluate anti-angiogenic and anti-vascular agents in clinical trials.

  • It allows to determine the functional response of tumor to the anti cancer agents on a microvascular level where parameters like vascular permeability are important biomarkers.
  • It is a non-invasive technique with low restrictions to patient comfort and is the method of choice to follow-up drug action in tumor and surrogate tissues.
  • It directly reflects the impact of the therapeutic drug on tumor state by angiogenesis assessment.
   

               
DCE-MRI data analysis is performed by an in-house software analysis tool

  • written in Matlab according to GCP-requirements,
  • to determine pharmacological parameter (Ktrans, kep) by pharmacokinetic modelling which are related to physiological parameters like vessel permeability and extra-vascular volume.
  • with pharmacodynamic models to analyze clinical and pre clinical MRI data,
  • with region of interest (ROI) and pixel wise analysis,
  • with handling of 2D, 3D and multi echo data sets,
  • with an user-friendly graphical user interface and
  • with a flexible design to meet the demands in the progress of modeling and new study trials.

  • (please click for magnified image) Screenshot example of the analysis tool.


MRDAC provides a complete package for the implementation of clinical phase trials including standard and advanced DCE-MRI measurement protocols and DCE-MRI analysis tools using professional software.
MRDAC has more than 10 years experience performing DCE-MRI examinations and analysis in the context of clinical trials.

There are allways ongoing clincial trials in collaboration with the Center of Tumorbiology. For more information be referred to the pages of our clinical partner: Center of Tumorbiology.

Publications - Books

  • Strecker R, Hennig J:
    DCE-MRI. In: Joachim Drevs (Hrsg): Tumorangiogenese- Grundlagen und therapeutische Ansätze. ,
    1. Auflage. Bremen: Uni-Med Science, 2005; 37-40 (4.3.1)

  • Büchert M, Fasol U:
    Bildgebende Verfahren zur Beurteilung der Effiktivität antiangiogener Wirkprinzipien. In: Klaus Mross (Hrsg): Angiogeneseinhibition in der Onkologie. ,
    1. Auflage . Bremen: Uni-Med Science, 2007; 55-70 (6.)

Publications - Scientific articles
  • A Thomas, B Morgan, J Drevs, A Jivan, M Buechert, M Horsfield, J Hennig, K Mross, A Henry, H Ball, B Peng, S Fuxius, C Unger, K 'Byrne, D Laurent, M Dugan, W Steward,
    Pharmacodynamic Results Using Dynamic Contrast Enhanced Magnetic Resonance Imaging, of 2 Phase 1 Studies of the VEGF Inhibitor PTK787/ZK 222584 in Patients with Liver Metastases from Colorectal Cancer.
    Meeting: 2001 ASCO Annual Meeting Abstract No: 279

  • Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt J, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, Marmé D.:
    PTK787/ZK 222584, a specific Vascular Endothelial Growth Factor-Receptor Tyrosine Kinase Inhibitor, Affects the anatomy of the Tumor Vascular Bed and the Functional Vascular Properties as detected by dynamic enhanced Magnetic Resonance Imaging.
    Cancer Res, 2002; 62: 4015-4022.

  • Strecker R, Scheffler K, Büchert M, Mross K, Drevs J, Hennig J.:
    DCE-MRI in clinical trials: data acquisition techniques and analysis methods.
    Int J Clin Pharm Th, 2003; 41 (12) : 603-605.

  • Morgan B, Thomas AL, Drevs J, Hennig J, Buechert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O’Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP.:
    Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    J Clin Oncol, 2003; 21 (21) : 3955-3964.

  • M. Medinger, K. Mross, U. Zirrgiebel, R. Strecker, C. Wheeler, G. Clack, J. Lewis, T. A. Puchalski, C. Unger, J. Drevs;
    Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases.
    Meeting: 2004 ASCO Annual Meeting &xnbsp; Abstract No: 3055 &xnbsp;

  • Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D, Unger C.:
    Phase I Clinical and Pharmacokinetic Study of PTK/ZK, a multiple VEGF Receptor Inhibitor, in Patients with Liver Metastases from Solid Tumours.
    Eur J Cancer, 2005; 41 (9) : 1291-1299.

  • K. B. Mross, D. Gmehling, A. Frost, F. Baas, R. Strecker, J. Hennig, P. Stopfer, M. Stefanic, G. Stehle, L. de Rossi
    A clinical Phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients
    J Clin Oncol (Meetings abstracts) 23(16s): 3031 (2005)

  • J. Drevs, M. Medinger, K. Mross, U. Zirrgiebel, R. Strecker, C. Unger, T. A. Puchalski, N. Fernandes, J. Roberston, P. Siegert
    Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors
    J Clin Oncol (Meetings abstracts) 23(16s): 3002 (2005)

  • C. Morris, J. Jurgensmeier, J. Robertson, S. Hollis, T. Puchalski, H. Young, R. Strecker, J. Kendrew, S. Wedge, J. Drevs
    AZD2171, an oral, highly potent, and reversible inhibitor of VEGFR, signaling with potential for the treatment of advanced colorectal cancer
    Meeting: 2006 ASCO Gastrointestinal Cancers Symposium &xnbsp; Abstract No: 242 &xnbsp;

  • Joachim Drevs, Patrizia Siegert, Michael Medinger, Ralph Strecker, Ute Zirrgiebel, Jan Harder, Hubert Blum, Jane Robertson, Juliane M Jürgensmeier, Thomas A Puchalski, Helen Young, Owain Saunders and Clemens Unger;
    Phase I clinical study of AZD2171, an oral, highly potent VEGF signaling inhibitor, in patients with advanced solid tumors;
    Journal of Clinical Oncology J Clin Oncol. 2007 Jul 20;25(21):3045-54.

  • Steinbild S, Arends J, Medinger M, Häring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K.
    Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
    Onkologie, 2007; 30 (12) : 629-635

  • Strumberg D, Schultheis B, Adamietz IA, Christensen O, Buechert M, Kraetzschmar J, Rajagopalan P, Ludwig M, Frost A, Steinbild S, Scheulen ME, Mross K.
    Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
    British journal of cancer 2008;99(10):1579-1585.

  • Sauerbier S, Palmowski M, Vogeler M, Nagursky H, Al-Ahmad A, Fisch D, Hennig J, Schmelzeisen R, Gutwald R, Fasol U.
    Onset and Maintenance of Angiogenesis in Biomaterials: In Vivo Assessment by Dynamic Contrast-Enhanced MRI.
    Tissue Eng Part C Methods 2009.


Contact
Search
Home
Qualitiy Management
impressum